product name: pomalidomide
synonyms: pomalidomide high quality;pomalidomide,pomalyst;actimid (celgene);4-amino-2-(2,6-dioxopiperidin-3-yl)isoindole-1,3-dione;pomalidomide high quality 19171-19-8;pomalidomide, 99%, a inhibitor of tnf-α;4-amino-2-(2,6-dioxo-piperidin-3-yl)-1h-isoindol-1,3(2h)-dione;4-amino-2-(2,6-dioxo-3-piperidyl)isoindoline-1,3-dione
cas: 19171-19-8
mf: c13h11n3o4
mw: 273.24
einecs: 805-902-5
melting point 318.5 - 320.5°
boiling point 582.9±45.0 °c(predicted)
density 1.570±0.06 g/cm3(predicted)
storage temp. 2-8°c
solubility dmso: ≥14mg/ml
pka 10.75±0.40(predicted)
form powder
color yellow
uses pomalidomide inhibits lps-induced tnf-α release with ic50 of 13 nm
uses pomalidomide is a thalidomide derivative, a potent inhibitor of tnf-α production. it is an antiinflammatory and antitumor agent used in the treatment of multiple myeloma.
uses pomalidomide is a second generation immunomodulator, tnf-α inhibitor, and thalidomide analog. an inhibitor of lps-induced tnfαrelease.

pomalidomide inhibits lps-induced tnf-α release with ic50 of 13 nm in pbmcs.
pomalidomide inhibits lipopolysaccharide (lps) stimulated tnf-alpha release in human pbmc and in human whole blood with ic50 values of 13 nm and 25 nm, respectively. pomalidomide inhibits the growth of t regulatory cells which is stimulated by il-2 with an ic50 of ~1 μm. treatment with pomalidomide (6.4 nm-10 μm) increases the production of il-2 in human peripheral blood t cells, and is slightly more potent in the cd4+ subset than in the cd8+ subset. pomalidomide is significantly more potent than cc-5013 at elevating il-2, il-5, and il-10 levels, but only slightly more potent than cc-5013 at elevating ifn-γ levels.
pomalidomide enhances see and raji cells induced ap-1 transcriptional activity in jurkat cells in a dose-dependent manner, with a maximal enhancement of 4-fold at 1 μm. exposure of raji cells to various concentrations of pomalidomide (2.5-40 μg/ml) for 48 hours leads to a significant decrease in cell proliferation and dna synthesis. there is a reduction of ~40% compared to vehicle-treated controls.